Zhicheng Liu

Zhicheng Liu

Auto-generated profile, based on publicly available information

Zhicheng Liu

Department of Urology Sun Yat‐sen University Cancer Center Guangzhou China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in European Urology Oncology
Verified
Journal Article
Open access
XTXingliang Tan
Xingliang Tan
ZLZhicheng Liu
Zhicheng Liu
TCTaonong Cai
Taonong Cai
YWYanjun Wang
Yanjun Wang
ZWZhiming Wu
Zhiming Wu
KYKai Yao
Kai Yao
Guidelines recommend intravesical instillation of bacillus Calmette-Guérin (BCG) as the first-choice treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). However, there is no therapeutic biomarker for predicting BCG efficacy, especially in high-risk cases with high failure rates. HER2 expression is considered a prognostic factor for bladder cancer. To elucidate the predictive value and significance of HER2 expression in patients with BCG-exposed NMIBC. A total of 454 patients with NMIBC were included. All patients started BCG intravesical instillation (1.2 × 108 CFU, strain D2PB302) 2-6 wk after transurethral resection of bladder tumor and received 19 treatments over a period of 1 yr. HER2 immunohistochemistry (IHC) results available for 314 patients. The outcomes investigated were recurrence-free survival (RFS) and progression-free survival (PFS). Outcome relationships were explored using multivariable Cox regression and log-rank analysis. In the IHC population, 35.7% of patients had HER2 overexpression (IHC score 2/3+). This group had a poor 5-yr RFS rate of 16.5%, in comparison to 68.0% in the group with low HER2 expression (p < 0.001). Patients with high-risk NMIBC and HER2 overexpression had the highest risk of BCG treatment failure, with 5-yr RFS and PFS rates of 19.0% and 58.2%, respectively. Conversely, HER2-negative (IHC score 0) patients with high-risk NMIBC experienced a long-term BCG benefit, with 5-yr RFS and PFS rates of 80.8% and 92.1%, respectively. Limitations include the retrospective study design and the limited details regarding BCG use. HER2 was an independent predictor of poor BCG efficacy in NMIBC. Patients with high-risk NMIBC and HER2 overexpression had the highest risk of disease recurrence and progression after exposure to BCG. Anti-HER2 targeted therapies could be considered for these patients. Measurement of blood levels of the protein HER2 can be used to predict outcomes after BCG (bacillus Calmette-Guérin) bladder therapy for patients with intermediate- or high-risk non-muscle-invasive bladder cancer. Measurement results for HER2 may help in guiding personalized treatment for these patients.

7 October 2025 in Cancer Medicine
Verified
Journal Article
Open access
ZLZhicheng Liu
Zhicheng Liu
XTXingliang Tan
Xingliang Tan
ZWZhiming Wu
Zhiming Wu
YTYi Tang
Yi Tang
QZQianghua Zhou
Qianghua Zhou
KYKai Yao
Kai Yao
Background: HER2 expression in primary versus metastatic tumors in advanced Extramammary Paget's Disease (EMPD) remains inadequately characterized. This investigation aimed to assess HER2 expression heterogeneity between primary tumors and metastatic lymph nodes (LNs) in patients with advanced EMPD and to assess the prognostic value of HER2 expression and other pathological factors in determining the therapeutic value of HER2 targeting. Methods: We included 170 patients diagnosed with primary EMPD. Survival outcomes were analyzed using multivariate Cox regression and log‐rank analysis, while inconsistencies in HER2 expression between primary and metastatic LNs were assessed using the kappa coefficient. Results: HER2 high‐expression was observed in 71.6% of primary tumors and 68.8% of metastatic LNs, with high HER2 expression correlating with poorer overall survival. Multivariate Cox analysis identified advanced N stage and HER2 high‐expression in primary tumors as independent poor prognostic factors. In 31 paired samples, the discordance rate of HER2 status between primary tumors and corresponding LNs was 35.48% ( n = 11) (Kappa 0.11, 95% CI −0.26 to 0.47; p = 0.540), with 19.4% of cases showing a shift from high HER2 expression in primary tumors to low expression in metastatic LNs. Patients treated with disitamab vedotin had an 80% objective response rate (ORR) and a 100% disease control rate (DCR), with no adverse events above grade 3–4. Conclusion: HER2 was frequently expressed in both primary tumors and metastatic LNs in EMPD patients, though heterogeneity was observed. HER2 status should be assessed in both primary and metastatic sites. Disitamab vedotin shows promise for treating HER2‐positive advanced EMPD, warranting further study.